Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

Enveda, a biotech startup that uses AI to observe caller drugs successful the earthy world, has raised a $311 cardinal Series E astatine a $2 cardinal valuation. The caller funding, which was led by Catalio Capital Management, with information from Iconiq and others, doubles the valuation Enveda achieved 12 months ago.

The thought down Enveda is that almighty medicines could beryllium harnessed from plants and microbes, alternatively than synthesized from scratch successful a lab. Viswa Colluru, an aboriginal worker of Recursion Pharmaceuticals, founded Enveda successful 2019 to velocity up the process of discovering these caller drugs utilizing AI and different techniques.

While AI hasn’t yet produced immoderate FDA-approved drugs, Enveda is among the question of companies advancing AI-discovered candidates into quality objective trials. The startup is presently investigating respective drugs successful patients, including 1 targeting terrible tegument conditions and different designed to assistance support value nonaccomplishment aft stopping GLP-1s.